黑色素瘤相关抗原A基因在乳腺癌中的表达及其临床意义

doi:10.3969/j.issn.1004-616x.2022.03.004

癌变·畸变·突变 ›› 2022, Vol. 34 ›› Issue (3): 184-191.doi: 10.3969/j.issn.1004-616x.2022.03.004

黑色素瘤相关抗原A基因在乳腺癌中的表达及其临床意义

范晓杰¹, 李清靖², 谷丽娜³, 桑梅香³, 单保恩³

1. 河北医科大学第四医院病理科, 河北石家庄 050011;
2. 河北医科大学第四医院检验科, 河北石家庄 050011;
3. 河北医科大学第四医院科研中心, 河北石家庄 050011

收稿日期:2022-01-10 修回日期:2022-05-06 发布日期:2022-06-10
通讯作者: 单保恩
作者简介:范晓杰,E-mail:fanxiaojierf@163.com
基金资助:
河北省医学科学研究重点课题资助项目(20190718)

Expression of melanoma-associated antigen A gene family in breast cancer and its clinical significance

FAN Xiaojie¹, LI Qingjing², GU Lina³, SANG Meixiang³, SHAN Baoen³

1. Department of Pathology, the Fourth Hospital of Hebei Medical University, Shijiazhuang 050011;
2. Department of Clinical Laboratory, the Fourth Hospital of Hebei Medical University, Shijiazhuang 050011;
3. Scientific Research Center, the Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, Hebei, China

Received:2022-01-10 Revised:2022-05-06 Published:2022-06-10

摘要/Abstract

摘要： 目的: 探讨黑色素瘤相关抗原A家族(MAGE-As)在乳腺癌患者外周血及组织中的表达,并分析其与乳腺癌患者临床病理学指标及预后的关系。方法: 采用多重巢式PCR法检测106例乳腺癌患者和30例健康志愿者外周血中MAGE-As m RNA的表达水平,并利用限制性内切酶酶切法,鉴定该家族成员MAGE-A1、A2、A3、A4和A6的表达情况。采用免疫组织化学法检测了106例乳腺癌组织蜡块中MAGE-As蛋白的表达情况,同时分析外周血中MAGE-As mRNA表达与其相应肿瘤组织中MAGE-As蛋白的表达的相关性。结果: MAGE-As mRNA在乳腺癌患者外周血中阳性表达率为40.5%(43/106)。MAGE-A1、A2、A3、A4和A6的表达率分别为10.3%(11/106)、19.8%(21/106)、15.1%(16/106)、13.2%(14/106)和5.7%(6/106),MAGE-As表达率的顺序为A2>A3>A4>A1>A6。MAGE-As mRNA阳性表达与患者年龄、肿瘤大小、临床分期、淋巴结转移相关(P<0.05)。乳腺癌患者外周血中MAGE-As mRNA表达水平与其相应肿瘤组织中蛋白水平的表达呈正相关(r=0.368,P<0.01)。MAGE-As各亚型(MAGE-A1、A2、A3、A4和A6)阳性表达率与乳腺癌患者5年生存率相关(P<0.01);MAGE-As表达及淋巴结转移可作为乳腺癌患者5年生存率的独立预后影响因素(均P<0.01)。结论: MAGE-As可能作为检测乳腺癌患者外周血中循环肿瘤细胞的特异性生物标志物,其表达与乳腺癌患者预后相关。乳腺癌患者外周血中MAGE-As检测可作为监测乳腺癌预后的重要指标。

关键词: 乳腺癌, 黑色素瘤相关抗原A家族, 外周血, 多重巢式PCR

Abstract: OBJECTIVE: To investigate expressions of melanoma-associated antigen A family (MAGE-As)in peripheral blood and cancer tissues from breast cancer patients,and to analyze their relationships with clinical parameters. METHODS: Expression levels of MAGE-As mRNA in peripheral blood of 106 breast cancer patients and 30 healthy controls were detected by multi-nested PCR,and expression levels of MAGE-A1,A2,A3,A4 and A6 were identified by restriction endonuclease digestion method.Expressions of MAGE-As protein in paraffin-embedded tissues of cancer tissues were detected by immunohistochemistry.Correlations between expressions of MAGE-As mRNA in peripheral blood and of MAGE-As protein in corresponding tumor tissues were analyzed. RESULTS: Positive expression rate of MAGE-As mRNA in the blood samples from patients was 40.5%(43/106).Expression rates of MAGE-A1,A2,A3,A4 and A6 were 10.3%(11/106),19.8%(21/106),15.1%(16/106),13.2%(14/106) and 5.7%(6/106),respectively.The sequence of MAGE-As gene expressions was A2>A3>A4>A1>A6.The MAGE-As mRNA expression was positively correlated with age,tumor size,clinical stage and lymph node metastasis (P<0.05).Expressions of MAGE-As mRNA in blood samples of patients were positively correlated with expression of MAGE-As protein in corresponding tumor tissues (r=0.368,P<0.01).Positive expressions of MAGE-As subtypes (MAGE-A1,A2,A3,A4 and A6)were correlated with 5-year survival rates of breast cancer patients (P<0.01).MAGE-As expression and lymph node metastasis were independent prognostic factors for 5-year survival of these patients (all P<0.01). CONCLUSION: MAGE-As may be a specific biomarker for detection of circulating tumor cells in peripheral blood of breast cancer patients,and its expression was correlated with the prognosis of these patients.MAGE-As in peripheral blood of breast cancer patients may be useful as an important biomarker to monitor prognosis of breast cancer.

Key words: breast cancer, MAGE-As, peripheral blood, multiplex semi-nested PCR

中图分类号:

R737.9

范晓杰, 李清靖, 谷丽娜, 桑梅香, 单保恩. 黑色素瘤相关抗原A基因在乳腺癌中的表达及其临床意义[J]. 癌变·畸变·突变, 2022, 34(3): 184-191.

FAN Xiaojie, LI Qingjing, GU Lina, SANG Meixiang, SHAN Baoen. Expression of melanoma-associated antigen A gene family in breast cancer and its clinical significance[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(3): 184-191.

参考文献

[1] SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
[2] LEI S Y, ZHENG R S, ZHANG S W, et al. Global patterns of breast cancer incidence and mortality:a population-based cancer registry data analysis from 2000 to 2020[J]. Cancer Commun(Lond), 2021, 41(11):1183-1194.
[3] SANG M X, WU X H, FAN X J, et al. MAGE-A family serves as poor prognostic markers and potential therapeutic targets for epithelial ovarian cancer patients:a retrospective clinical study[J]. Gynecol Endocrinol, 2017, 33(6):480-484.
[4] 谷丽娜,尹丹静,桑梅香,等.黑色素瘤相关抗原A基因家族在食管癌患者外周血中的表达及其临床意义[J].中国肿瘤生物治疗杂志, 2018, 25(8):803-809.
[5] TELLEZ-GABRIEL M, BROWN H K, YOUNG R, et al. The challenges of detecting circulating tumor cells in sarcoma[J].Front Oncol, 2016, 6:202.
[6] LIOTTA L A, SAIDEL M G, KLEINERMAN J. The significance of hematogenous tumor cell clumps in the metastatic process[J]. Cancer Res, 1976, 36(3):889-894.
[7] MAGBANUA M J M, RUGO H S, WOLF D M, et al. Expanded genomic profiling of circulating tumor cells in metastatic breast cancer patients to assess biomarker status and biology over time(CALGB 40502 and CALGB 40503, alliance)[J]. Clin Cancer Res, 2018, 24(6):1486-1499.
[8] STRATI A, NIKOLAOU M, GEORGOULIAS V, et al.Prognostic significance of TWIST1, CD24, CD44, and ALDH1transcript quantification in EpCAM-positive circulating tumor cells from early stage breast cancer patients[J]. Cells, 2019, 8(7):652.
[9] CABEL L, BERGER F, COTTU P, et al. Clinical utility of circulating tumour cell-based monitoring of late-line chemotherapy for metastatic breast cancer:the randomised CirCe01 trial[J].Br J Cancer, 2021, 124(7):1207-1213.
[10] GOODMAN C R, SPEERS C W. The role of circulating tumor cells in breast cancer and implications for radiation treatment decisions[J]. Int J Radiat Oncol Biol Phys, 2021, 109(1):44-59.
[11] MILLNER L M, LINDER M W, VALDES R Jr. Circulating tumor cells:a review of present methods and the need to identify heterogeneous phenotypes[J]. Ann Clin Lab Sci, 2013,43(3):295-304.
[12] PRIETO-GARCÍA E, DÍAZ-GARCÍA C V, GARCÍA-RUIZ I,et al. Epithelial-to-mesenchymal transition in tumor progression[J]. Med Oncol, 2017, 34(7):122.
[13] NIETO M A, HUANG R Y J, JACKSON R A, et al. Emt:2016[J]. Cell, 2016, 166(1):21-45.
[14] WANG Y X, LI F L, DU L X, et al. The co-expression of melanoma-antigen family a proteins and New York esophageal squamous cell carcinoma-1 in breast cancer:a pilot study[J].Cancer Manag Res, 2021, 13:6123-6128.
[15] OH C, KIM H R, OH S, et al. Epigenetic upregulation of MAGE-A isoforms promotes breast cancer cell aggressiveness[J]. Cancers, 2021, 13(13):3176.
[16] WANG H, SANG M, GENG C, et al. MAGE-A is frequently expressed in triple negative breast cancer and associated with epithelial-mesenchymal transition[J]. Neoplasma, 2016, 63(1):44-56.
[17] GU L N, SANG M X, YIN D J, et al. MAGE-A gene expression in peripheral blood serves as a poor prognostic marker for patients with lung cancer[J]. Thorac Cancer, 2018, 9(4):431-438.
[18] OTTE M, ZAFRAKAS M, RIETHDORF L, et al. MAGE-A gene expression pattern in primary breast cancer[J]. Cancer Res, 2001, 61(18):6682-6687.
[19] HAMZA A, SAKHI R, ALRAJJAL A, et al. Tumor size in breast carcinoma:gross measurement is important![J]. Int J Surg Pathol, 2018, 26(6):494-499.
[20] TEICHGRAEBER D C, GUIRGUIS M S, WHITMAN G J.Breast cancer staging:updates in the AJCC cancer staging manual, 8th edition, and current challenges for radiologists,from the AJR special series on cancer staging[J]. AJR Am J Roentgenol, 2021, 217(2):278-290.

黑色素瘤相关抗原A基因在乳腺癌中的表达及其临床意义

Expression of melanoma-associated antigen A gene family in breast cancer and its clinical significance

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王绪娟, 罗永鑫, 李陈强, 王汝晋, 郑婷婷. 术前检查指标dNLR、SII、CRP/ALB对乳腺癌复发转移的预测价值[J]. 癌变·畸变·突变, 2022, 34(4): 284-288,323.
[2]	张月, 王耀一, 武雪亮, 张志生, 杨修明, 姜洋, 乔志飞, 梁晚平, 薛军. ¹²⁵I粒子联合AZD1152对三阴性乳腺癌细胞增殖和凋亡的影响[J]. 癌变·畸变·突变, 2022, 34(4): 295-299,306.
[3]	辛雨濛, 梁桓熙, 孙震晓. 甘草干姜汤抗小鼠乳腺癌实验研究[J]. 癌变·畸变·突变, 2022, 34(2): 88-92.
[4]	郭晓娟, 王金西, 牛广旭, 田云霄. EGFR与HER-2在不同分子类型乳腺癌中的表达及其相关性分析[J]. 癌变·畸变·突变, 2022, 34(2): 119-123,148.
[5]	辛雨濛, 梁桓熙, 余悦华, 孙震晓. 基于网络药理学和分子对接法预测甘草干姜汤抗乳腺癌的主要活性成分及作用机制[J]. 癌变·畸变·突变, 2022, 34(1): 7-13.
[6]	赵岩, 孙震晓. 二甲双胍抑制人MDA-MB-231细胞增殖及迁移的体外实验研究[J]. 癌变·畸变·突变, 2022, 34(1): 35-39.
[7]	方煜彤, 张群琛, 洪超群, 陈春发, 陈炯玉, 张任栋, 吴俊东. 乳腺癌中miR-221、miR-222表达水平对GATA3和FOXA1蛋白的影响及其作用机制[J]. 癌变·畸变·突变, 2021, 33(6): 435-441,460.
[8]	张世民, 赵瑞君. 蛋白酪氨酸磷酸酶受体J在乳腺癌组织中的表达及其与临床预后的相关性[J]. 癌变·畸变·突变, 2021, 33(4): 276-279,285.
[9]	程斌, 王新宇, 孙钰, 张家泰, 董淑英. 二甲双胍对DEHP和DBP诱导的MCF-7细胞增殖和迁移的抑制作用[J]. 癌变·畸变·突变, 2021, 33(3): 197-202.
[10]	罗娇, 张坤驰, 周莉. 三阴性乳腺癌细胞系MDA-MB-231与其脑转移细胞系中microRNA差异表达分析[J]. 癌变·畸变·突变, 2021, 33(3): 218-224.
[11]	李玮玮, 朱莹. 数据挖掘分析MYB家族在乳腺癌中的表达及其预后评估价值[J]. 癌变·畸变·突变, 2020, 32(6): 414-422.
[12]	陈绵龄, 马硕一. miR-21通过靶向PDCD4调控三阴性乳腺癌细胞的迁移和侵袭[J]. 癌变·畸变·突变, 2020, 32(4): 292-297.
[13]	张惠娟, 黄大元, 张洁, 唐海欧, 谢安心, 谭敦勇. SF1a-PRLR和ΔS2 SF1a-PRLR对乳腺癌MCF-7细胞增殖和microRNA表达的影响[J]. 癌变·畸变·突变, 2020, 32(3): 203-208.
[14]	孙全武, 杜小平, 郝杰, 时荣, 刘波, 黄海云. 伴病理性乳头溢液的乳腺癌患者癌组织整合素β1的表达及意义[J]. 癌变·畸变·突变, 2019, 31(5): 368-372.
[15]	王兰, 张永东, 郭红云, 王涛, 王海涛, 郭欢, 杨碎胜, 李晓琴, 苏海翔. XRCC3基因多态性与西北地区妇女乳腺癌的关联性研究[J]. 癌变·畸变·突变, 2019, 31(5): 392-396,400.